Oncological agents, specifically immune checkpoint inhibitors and tyrosine kinase inhibitors, represent an increasing cause of idiosyncratic drug-induced liver injury

Drug pricing and affordability, FDA drug approvals, clinical trial design, drug shortages, insurer coverage, pharmaceutical regulation, and medication access.

Cancer treatment, oncology drug access, hematologic malignancies, and cancer drug policy.